State-of-the-art review: allogeneic stem ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
Author(s) :
Mclornan, Donal [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Robin, Marie [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Chalandon, Yves [Auteur]
Harrison, Claire N. [Auteur]
Kroger, Nicolaus [Auteur]
Yakoub-Agha, Ibrahim [Auteur]

Lille Inflammation Research International Center - U 995 [LIRIC]
Robin, Marie [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Chalandon, Yves [Auteur]
Harrison, Claire N. [Auteur]
Kroger, Nicolaus [Auteur]
Journal title :
Haematologica
Abbreviated title :
Haematologica
Volume number :
104
Publication date :
2019-04-01
ISSN :
1592-8721
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to an ever-evolving armamentarium of novel agents to treat patients, ...
Show more >Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to an ever-evolving armamentarium of novel agents to treat patients, although allogeneic hematopoietic stem cell transplantation remains the only curative approach. Improvements in donor selection, conditioning regimens, disease monitoring and supportive care have led to augmented survival after transplantation. Nowadays, there are comprehensive guidelines concerning allogeneic hematopoietic stem cell transplantation for patients with myelofibrosis. However, it commonly remains difficult for both physicians and patients alike to weigh up the risk-benefit ratio of transplantation given the inherent heterogeneity regarding both clinical course and therapeutic response. In this timely review, we provide an up-to-date synopsis of current transplantation recommendations, discuss usage of JAK inhibitors before and after transplantation, examine donor selection and compare conditioning platforms. Moreover, we discuss emerging data concerning the impact of the myelofibrosis mutational landscape on transplantation outcome, peritransplant management of splenomegaly, poor graft function and prevention/management of relapse.Show less >
Show more >Advances in understanding the pathogenesis and molecular landscape of myelofibrosis have occurred over the last decade. Treating physicians now have access to an ever-evolving armamentarium of novel agents to treat patients, although allogeneic hematopoietic stem cell transplantation remains the only curative approach. Improvements in donor selection, conditioning regimens, disease monitoring and supportive care have led to augmented survival after transplantation. Nowadays, there are comprehensive guidelines concerning allogeneic hematopoietic stem cell transplantation for patients with myelofibrosis. However, it commonly remains difficult for both physicians and patients alike to weigh up the risk-benefit ratio of transplantation given the inherent heterogeneity regarding both clinical course and therapeutic response. In this timely review, we provide an up-to-date synopsis of current transplantation recommendations, discuss usage of JAK inhibitors before and after transplantation, examine donor selection and compare conditioning platforms. Moreover, we discuss emerging data concerning the impact of the myelofibrosis mutational landscape on transplantation outcome, peritransplant management of splenomegaly, poor graft function and prevention/management of relapse.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Submission date :
2024-01-30T10:26:59Z
2024-01-31T12:36:13Z
2024-01-31T12:36:13Z
Files
- 8840-Article Text-63017-1-10-20200724.pdf
- Non spécifié
- Open access
- Access the document
Except where otherwise noted, this item's license is described as Attribution-NonCommercial 3.0 United States